Browse the evidence

Replacing servings of low-quality carbohydrates or animal protein with high-quality carbohydrates or plant protein reduces phenotypic age acceleration (PhenoAgeAccel).

To slow biological aging, focus on swapping food sources rather than just cutting calories. Replace one serving of refined grains, sugary drinks, or animal meat with one serving of whole grains, vegetables, nuts, soy, or plant proteins. This substitution is associated with a significant reduction in biological age markers.

High-quality carbohydrate intake is associated with reduced phenotypic age acceleration, but the relationship is non-linear, with potential adverse effects at excessive intake levels.

While high-quality carbohydrates (whole grains, vegetables) generally slow aging, the benefit is not linear. Very high intake may not provide additional benefits and could be detrimental. Aim for a balanced intake of these foods as part of a substitution strategy rather than maximizing them.

Higher relative intake of dietary protein is inversely associated with the risk of coronary artery disease (CAD), based on observational data.

If you are concerned about coronary artery disease, this study suggests that ensuring adequate protein intake may be beneficial. Higher relative protein intake was linked to a lower risk of CAD. Include protein-rich foods in your diet. Consult your doctor for personalized advice, especially if you have existing kidney conditions.

In older women, substituting total or animal protein with fat or carbohydrates is negatively associated with appendicular skeletal muscle mass (ASMM) in cross-sectional analyses, but this association disappears in longitudinal analyses over 20 years.

For older women, simply eating more protein than fat or carbs might not protect muscle mass in the long run (20 years). While cross-sectional data shows a link between lower protein and lower muscle mass, long-term tracking shows no clear benefit. Focus on overall diet quality and physical activity rather than just maximizing protein intake.

A Moderate Carbohydrate-Low Protein (MCLP) diet is the most effective macronutrient ratio for reducing triglycerides compared to a moderate fat-low protein (MFLP) control diet.

If your main health concern is high triglycerides rather than weight loss, a diet with moderate carbohydrates (30-50% of calories) and low protein (≤30% of calories) is likely more effective than very low-carb diets. This ratio outperforms standard moderate-fat diets for this specific lipid marker.

Ketogenic, Mediterranean, and DASH diets are effective for preventing atherosclerosis due to their low carbohydrate content, high vegetable/fruit/berry content, and antioxidant richness.

Adopt a Ketogenic, Mediterranean, or DASH diet to prevent atherosclerosis. Focus on low-carbohydrate, high-vegetable, fruit, and antioxidant-rich foods.

Low-carbohydrate diets improve long-term cardiovascular risk factors (specifically triglycerides and HDL cholesterol) compared to balanced diets, despite no long-term difference in weight loss.

Even if your weight stabilizes to match a balanced diet after a year, your blood lipid profile may improve on a low-carb diet. Specifically, expect lower triglycerides and higher HDL ('good') cholesterol, which are positive markers for heart health.

Emotional eating is associated with the consumption of energy-dense, nutrient-poor foods (sugary and high-fat snacks), contributing to weight gain.

Emotional eaters tend to choose high-fat, sugary snacks when stressed. To mitigate weight gain, be aware that your food choices under stress are likely to be energy-dense. Planning healthier snacks or strategies to manage stress directly can reduce the intake of these specific food types.

Consumption of saturated fatty acids reduces slow-wave sleep duration and increases nighttime awakenings, whereas consumption of unsaturated fatty acids (specifically from fatty fish) improves sleep regulation and increases drowsiness.

Replace saturated fats (fried foods, animal fats) with unsaturated fats, particularly omega-3s from fatty fish like salmon or mackerel. This shift may help you stay asleep longer and improve sleep quality.

Plant-based meat alternatives (PBMAs) generally exhibit lower energy, total fat, and saturated fat content, but higher fiber and carbohydrate content compared to animal meat, though they often contain higher sodium levels and have lower amino acid bioavailability.

When choosing plant-based meat alternatives, expect lower saturated fat and higher fiber compared to animal meat, but be mindful of potentially higher sodium levels. Note that protein quality (bioavailability) may be lower than animal meat, so variety in protein sources is important. These products are not nutritionally identical to meat.

Omega-3 fatty acids (specifically fish oils) may be effective in treating MASLD, potentially synergistically with chicory acid.

Omega-3 fatty acids from fish oil may help reduce liver fat in MASLD. They are recommended in guidelines, though they are not a standalone cure.

Flavonoids inhibit glucose transporters (GLUT2, GLUT5, GLUT7), thereby reducing intestinal glucose and fructose absorption.

Eating flavonoid-rich foods might slightly slow down sugar absorption by affecting transporters in the gut. This is a subtle effect and should not replace a balanced diet, but it may offer some metabolic benefit.

Vegetarian diets do not significantly reduce the risk of gestational diabetes or hypertension in pregnant women compared to omnivorous diets.

If you are pregnant, switching to a vegetarian diet may not specifically reduce your risk of gestational diabetes or high blood pressure compared to a standard diet. Consult your doctor for personalized advice.

GLP-1RA users tend to overconsume saturated fat and total fat percentages, potentially exacerbating gastrointestinal side effects like nausea and constipation.

You are likely eating too much saturated fat, which can worsen nausea and constipation common with GLP-1RA. Try to shift some calories from fats to fiber-rich carbohydrates and protein to improve GI comfort and nutrient density.

In healthy adults, higher dietary saturated fat intake is independently associated with higher LDL-C, but this relationship is not dose-dependent across typical intake ranges and is largely explained by abdominal visceral adipose tissue (VAT) mass rather than the fat itself.

If you are healthy and have a normal BMI, simply reducing saturated fat might not significantly lower your LDL-C if you have high visceral fat. Focus on overall body composition and visceral fat reduction, as these factors appear to drive LDL-C levels more strongly than SFA intake alone in this population.

Reducing saturated fat intake has little or no effect on all-cause mortality, cardiovascular mortality, or cancer deaths in adults.

While reducing saturated fat is excellent for preventing heart attacks and strokes, you should not expect it to drastically extend your lifespan on its own. Focus on the quality of life and prevention of non-fatal cardiovascular events as the primary benefit.

Intravenous amino acid infusion improves muscle protein synthesis and reduces perioperative blood loss in total joint arthroplasty patients.

If your surgical team recommends intravenous amino acids during your joint replacement, it may help preserve muscle protein and reduce blood loss. This is a specific medical intervention that complements your surgery, not a substitute for post-operative nutrition.

Monounsaturated fat (MUFA) intake has a significant but weak correlation with multiple obesity and coronary indices (CI, AVI, BRI, WWI, AIP), suggesting a less pronounced impact on these specific metrics compared to SFA and PUFA.

In this study, monounsaturated fat (MUFA) intake was weakly correlated with various obesity and heart health markers. While MUFA is generally considered healthy, this study suggests its direct impact on these specific abdominal and coronary indices is less strong than that of saturated or polyunsaturated fats in this population.

Low-Carbohydrate High-Fat (LCHF) and Ketogenic diets do not significantly alter ALT levels in individuals with MASLD compared to control diets.

Current evidence from this meta-analysis does not support LCHF or Ketogenic diets as significantly effective for lowering liver enzymes (ALT) in people with MASLD compared to control diets. The wide variation in how 'low-carb' was defined across studies makes it difficult to draw firm conclusions, but it did not show the significant benefits seen with fasting or MedDiet.

High intake of saturated fat is not associated with increased risk of cardiovascular disease or mortality, and may be associated with lower total mortality and stroke risk in observational studies.

Observational data from large global cohorts suggests that saturated fat intake is not linked to higher heart disease or stroke risk, and may be linked to lower overall mortality. This challenges the standard advice to strictly limit these fats.

Semaglutide therapy alters energy partitioning, resulting in a greater proportion of fat-free mass loss relative to fat loss compared to predictions based on standard energy density models.

Semaglutide may cause you to lose more muscle mass relative to fat than standard dieting. Ensure you are consuming adequate protein and engaging in resistance training to mitigate this specific side effect.

Artificial Intelligence (AI) and machine learning models can significantly improve the prediction of obesity prevalence and risk by analyzing complex interactions between behavioral, metabolic, and environmental data.

Be open to using wearable technology and health apps that use AI to predict your obesity risk. These tools can provide personalized insights into your lifestyle and metabolic health, helping you make better decisions.

Combining GLP-1 receptor agonists with myostatin or activin type II receptor inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) preserves or increases lean mass while enhancing fat loss, addressing the risk of sarcopenia and metabolic slowdown associated with standard AOM therapy.

Current GLP-1 therapies can lead to muscle loss, which may hinder long-term weight maintenance. Emerging combination therapies that pair GLP-1 agonists with muscle-preserving antibodies (like bimagrumab or myostatin inhibitors) show promise in preclinical models for doubling fat loss while increasing lean mass. Patients should discuss these emerging options with their providers, especially if they are concerned about muscle loss.

Combined GIPR/GLP1R agonism lowers plasma triglyceride levels by increasing VLDL turnover (reduced hepatic VLDL-TG production and increased uptake by adipose tissue and liver).

Dual GIP/GLP-1 agonism improves lipid profiles by accelerating the clearance of triglyceride-rich lipoproteins (VLDL). This suggests that patients on these therapies may see significant improvements in triglyceride levels, which is a key risk factor for cardiovascular disease.